nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.469	1	CbGbCtD
Regorafenib—Traumatic liver injury—Riluzole—amyotrophic lateral sclerosis	0.0116	0.0809	CcSEcCtD
Regorafenib—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00845	0.0589	CcSEcCtD
Regorafenib—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00711	0.0495	CcSEcCtD
Regorafenib—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00647	0.0451	CcSEcCtD
Regorafenib—KDR—hindlimb—amyotrophic lateral sclerosis	0.00606	0.0434	CbGeAlD
Regorafenib—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00538	0.0375	CcSEcCtD
Regorafenib—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00522	0.0363	CcSEcCtD
Regorafenib—KDR—appendage—amyotrophic lateral sclerosis	0.0052	0.0372	CbGeAlD
Regorafenib—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.00514	0.0358	CcSEcCtD
Regorafenib—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00482	0.0336	CcSEcCtD
Regorafenib—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00391	0.0272	CcSEcCtD
Regorafenib—FGFR2—hindbrain—amyotrophic lateral sclerosis	0.00352	0.0252	CbGeAlD
Regorafenib—RAF1—hindbrain—amyotrophic lateral sclerosis	0.00325	0.0232	CbGeAlD
Regorafenib—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00315	0.022	CcSEcCtD
Regorafenib—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00286	0.0199	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00283	0.0197	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00277	0.0193	CcSEcCtD
Regorafenib—FLT4—embryo—amyotrophic lateral sclerosis	0.00263	0.0188	CbGeAlD
Regorafenib—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00254	0.0177	CcSEcCtD
Regorafenib—DDR2—spinal cord—amyotrophic lateral sclerosis	0.00246	0.0176	CbGeAlD
Regorafenib—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00245	0.0171	CcSEcCtD
Regorafenib—KIT—hindbrain—amyotrophic lateral sclerosis	0.00245	0.0175	CbGeAlD
Regorafenib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00242	0.0168	CcSEcCtD
Regorafenib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00242	0.0168	CcSEcCtD
Regorafenib—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00238	0.0166	CcSEcCtD
Regorafenib—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00237	0.0165	CcSEcCtD
Regorafenib—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00236	0.0164	CcSEcCtD
Regorafenib—RET—embryo—amyotrophic lateral sclerosis	0.00232	0.0166	CbGeAlD
Regorafenib—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00229	0.0159	CcSEcCtD
Regorafenib—FGFR2—embryo—amyotrophic lateral sclerosis	0.0022	0.0158	CbGeAlD
Regorafenib—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00218	0.0152	CcSEcCtD
Regorafenib—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00217	0.0151	CcSEcCtD
Regorafenib—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00214	0.0149	CcSEcCtD
Regorafenib—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00213	0.0149	CcSEcCtD
Regorafenib—ABL1—hindbrain—amyotrophic lateral sclerosis	0.00213	0.0152	CbGeAlD
Regorafenib—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00213	0.0148	CcSEcCtD
Regorafenib—TEK—embryo—amyotrophic lateral sclerosis	0.00211	0.0151	CbGeAlD
Regorafenib—DDR2—nervous system—amyotrophic lateral sclerosis	0.00207	0.0148	CbGeAlD
Regorafenib—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00205	0.0143	CcSEcCtD
Regorafenib—FLT1—embryo—amyotrophic lateral sclerosis	0.00204	0.0146	CbGeAlD
Regorafenib—RAF1—embryo—amyotrophic lateral sclerosis	0.00203	0.0145	CbGeAlD
Regorafenib—FGFR2—brainstem—amyotrophic lateral sclerosis	0.00202	0.0144	CbGeAlD
Regorafenib—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00202	0.014	CcSEcCtD
Regorafenib—DDR2—central nervous system—amyotrophic lateral sclerosis	0.00199	0.0143	CbGeAlD
Regorafenib—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00197	0.0137	CcSEcCtD
Regorafenib—MAPK11—nervous system—amyotrophic lateral sclerosis	0.00196	0.014	CbGeAlD
Regorafenib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00196	0.0136	CcSEcCtD
Regorafenib—DDR2—cerebellum—amyotrophic lateral sclerosis	0.00195	0.0139	CbGeAlD
Regorafenib—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00192	0.0134	CcSEcCtD
Regorafenib—PDGFRA—embryo—amyotrophic lateral sclerosis	0.00191	0.0137	CbGeAlD
Regorafenib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00189	0.0132	CcSEcCtD
Regorafenib—MAPK11—central nervous system—amyotrophic lateral sclerosis	0.00189	0.0135	CbGeAlD
Regorafenib—RAF1—brainstem—amyotrophic lateral sclerosis	0.00186	0.0133	CbGeAlD
Regorafenib—MAPK11—cerebellum—amyotrophic lateral sclerosis	0.00185	0.0132	CbGeAlD
Regorafenib—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00177	0.0123	CcSEcCtD
Regorafenib—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00175	0.0122	CcSEcCtD
Regorafenib—KDR—embryo—amyotrophic lateral sclerosis	0.00173	0.0124	CbGeAlD
Regorafenib—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00169	0.0118	CcSEcCtD
Regorafenib—FGFR1—medulla oblongata—amyotrophic lateral sclerosis	0.00166	0.0118	CbGeAlD
Regorafenib—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00163	0.0114	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.0016	0.0111	CcSEcCtD
Regorafenib—DDR2—brain—amyotrophic lateral sclerosis	0.00158	0.0113	CbGeAlD
Regorafenib—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00157	0.011	CcSEcCtD
Regorafenib—Infection—Riluzole—amyotrophic lateral sclerosis	0.00153	0.0107	CcSEcCtD
Regorafenib—KIT—embryo—amyotrophic lateral sclerosis	0.00153	0.0109	CbGeAlD
Regorafenib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00151	0.0105	CcSEcCtD
Regorafenib—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00151	0.0105	CcSEcCtD
Regorafenib—MAPK11—brain—amyotrophic lateral sclerosis	0.0015	0.0107	CbGeAlD
Regorafenib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.0015	0.0104	CcSEcCtD
Regorafenib—PDGFRB—embryo—amyotrophic lateral sclerosis	0.00149	0.0107	CbGeAlD
Regorafenib—RET—medulla oblongata—amyotrophic lateral sclerosis	0.00148	0.0106	CbGeAlD
Regorafenib—FGFR1—spinal cord—amyotrophic lateral sclerosis	0.00148	0.0106	CbGeAlD
Regorafenib—KIT—brainstem—amyotrophic lateral sclerosis	0.0014	0.01	CbGeAlD
Regorafenib—BRAF—cerebellum—amyotrophic lateral sclerosis	0.00138	0.00985	CbGeAlD
Regorafenib—TEK—medulla oblongata—amyotrophic lateral sclerosis	0.00135	0.00966	CbGeAlD
Regorafenib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00934	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00928	CcSEcCtD
Regorafenib—ABL1—embryo—amyotrophic lateral sclerosis	0.00133	0.00953	CbGeAlD
Regorafenib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00927	CcSEcCtD
Regorafenib—RET—spinal cord—amyotrophic lateral sclerosis	0.00132	0.00945	CbGeAlD
Regorafenib—Pain—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00919	CcSEcCtD
Regorafenib—EPHX2—cerebellum—amyotrophic lateral sclerosis	0.00132	0.00942	CbGeAlD
Regorafenib—FLT1—medulla oblongata—amyotrophic lateral sclerosis	0.0013	0.00934	CbGeAlD
Regorafenib—RAF1—medulla oblongata—amyotrophic lateral sclerosis	0.0013	0.00928	CbGeAlD
Regorafenib—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00879	CcSEcCtD
Regorafenib—FGFR2—spinal cord—amyotrophic lateral sclerosis	0.00126	0.00898	CbGeAlD
Regorafenib—ABL1—brainstem—amyotrophic lateral sclerosis	0.00122	0.00873	CbGeAlD
Regorafenib—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00122	0.0085	CcSEcCtD
Regorafenib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00122	0.0085	CcSEcCtD
Regorafenib—TEK—spinal cord—amyotrophic lateral sclerosis	0.0012	0.00861	CbGeAlD
Regorafenib—FGFR1—cerebellum—amyotrophic lateral sclerosis	0.00117	0.00838	CbGeAlD
Regorafenib—FLT1—spinal cord—amyotrophic lateral sclerosis	0.00116	0.00833	CbGeAlD
Regorafenib—RAF1—spinal cord—amyotrophic lateral sclerosis	0.00116	0.00828	CbGeAlD
Regorafenib—BRAF—brain—amyotrophic lateral sclerosis	0.00112	0.008	CbGeAlD
Regorafenib—RET—nervous system—amyotrophic lateral sclerosis	0.00111	0.00797	CbGeAlD
Regorafenib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00771	CcSEcCtD
Regorafenib—KDR—medulla oblongata—amyotrophic lateral sclerosis	0.0011	0.00789	CbGeAlD
Regorafenib—PDGFRA—spinal cord—amyotrophic lateral sclerosis	0.00109	0.0078	CbGeAlD
Regorafenib—RET—central nervous system—amyotrophic lateral sclerosis	0.00107	0.00767	CbGeAlD
Regorafenib—EPHX2—brain—amyotrophic lateral sclerosis	0.00107	0.00765	CbGeAlD
Regorafenib—FGFR2—nervous system—amyotrophic lateral sclerosis	0.00106	0.00757	CbGeAlD
Regorafenib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00735	CcSEcCtD
Regorafenib—RET—cerebellum—amyotrophic lateral sclerosis	0.00105	0.0075	CbGeAlD
Regorafenib—EPHA2—nervous system—amyotrophic lateral sclerosis	0.00104	0.00744	CbGeAlD
Regorafenib—FGFR2—central nervous system—amyotrophic lateral sclerosis	0.00102	0.00729	CbGeAlD
Regorafenib—TEK—nervous system—amyotrophic lateral sclerosis	0.00101	0.00726	CbGeAlD
Regorafenib—EPHA2—central nervous system—amyotrophic lateral sclerosis	0.001	0.00716	CbGeAlD
Regorafenib—FGFR2—cerebellum—amyotrophic lateral sclerosis	0.000995	0.00712	CbGeAlD
Regorafenib—KDR—spinal cord—amyotrophic lateral sclerosis	0.000983	0.00704	CbGeAlD
Regorafenib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000981	0.00683	CcSEcCtD
Regorafenib—FLT1—nervous system—amyotrophic lateral sclerosis	0.00098	0.00702	CbGeAlD
Regorafenib—KIT—medulla oblongata—amyotrophic lateral sclerosis	0.000977	0.00699	CbGeAlD
Regorafenib—TEK—central nervous system—amyotrophic lateral sclerosis	0.000976	0.00699	CbGeAlD
Regorafenib—RAF1—nervous system—amyotrophic lateral sclerosis	0.000975	0.00698	CbGeAlD
Regorafenib—Rash—Riluzole—amyotrophic lateral sclerosis	0.000973	0.00678	CcSEcCtD
Regorafenib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000972	0.00677	CcSEcCtD
Regorafenib—Headache—Riluzole—amyotrophic lateral sclerosis	0.000967	0.00673	CcSEcCtD
Regorafenib—FLT4—brain—amyotrophic lateral sclerosis	0.000964	0.0069	CbGeAlD
Regorafenib—PDGFRB—medulla oblongata—amyotrophic lateral sclerosis	0.000955	0.00683	CbGeAlD
Regorafenib—TEK—cerebellum—amyotrophic lateral sclerosis	0.000954	0.00683	CbGeAlD
Regorafenib—FGFR1—brain—amyotrophic lateral sclerosis	0.000951	0.0068	CbGeAlD
Regorafenib—FLT1—central nervous system—amyotrophic lateral sclerosis	0.000944	0.00675	CbGeAlD
Regorafenib—RAF1—central nervous system—amyotrophic lateral sclerosis	0.000938	0.00672	CbGeAlD
Regorafenib—FLT1—cerebellum—amyotrophic lateral sclerosis	0.000923	0.0066	CbGeAlD
Regorafenib—PDGFRA—nervous system—amyotrophic lateral sclerosis	0.000919	0.00657	CbGeAlD
Regorafenib—RAF1—cerebellum—amyotrophic lateral sclerosis	0.000917	0.00656	CbGeAlD
Regorafenib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000916	0.00638	CcSEcCtD
Regorafenib—PDGFRA—central nervous system—amyotrophic lateral sclerosis	0.000884	0.00633	CbGeAlD
Regorafenib—KIT—spinal cord—amyotrophic lateral sclerosis	0.000872	0.00624	CbGeAlD
Regorafenib—PDGFRA—cerebellum—amyotrophic lateral sclerosis	0.000864	0.00619	CbGeAlD
Regorafenib—PDGFRB—spinal cord—amyotrophic lateral sclerosis	0.000851	0.00609	CbGeAlD
Regorafenib—ABL1—medulla oblongata—amyotrophic lateral sclerosis	0.000851	0.00609	CbGeAlD
Regorafenib—RET—brain—amyotrophic lateral sclerosis	0.000851	0.00609	CbGeAlD
Regorafenib—KDR—nervous system—amyotrophic lateral sclerosis	0.000829	0.00593	CbGeAlD
Regorafenib—FGFR2—brain—amyotrophic lateral sclerosis	0.000808	0.00579	CbGeAlD
Regorafenib—KDR—central nervous system—amyotrophic lateral sclerosis	0.000798	0.00571	CbGeAlD
Regorafenib—EPHA2—brain—amyotrophic lateral sclerosis	0.000794	0.00569	CbGeAlD
Regorafenib—KDR—cerebellum—amyotrophic lateral sclerosis	0.00078	0.00558	CbGeAlD
Regorafenib—TEK—brain—amyotrophic lateral sclerosis	0.000775	0.00555	CbGeAlD
Regorafenib—ABL1—spinal cord—amyotrophic lateral sclerosis	0.000759	0.00543	CbGeAlD
Regorafenib—FLT1—brain—amyotrophic lateral sclerosis	0.000749	0.00536	CbGeAlD
Regorafenib—RAF1—brain—amyotrophic lateral sclerosis	0.000745	0.00533	CbGeAlD
Regorafenib—KIT—nervous system—amyotrophic lateral sclerosis	0.000734	0.00526	CbGeAlD
Regorafenib—PDGFRB—nervous system—amyotrophic lateral sclerosis	0.000717	0.00513	CbGeAlD
Regorafenib—KIT—central nervous system—amyotrophic lateral sclerosis	0.000707	0.00506	CbGeAlD
Regorafenib—PDGFRA—brain—amyotrophic lateral sclerosis	0.000702	0.00503	CbGeAlD
Regorafenib—KIT—cerebellum—amyotrophic lateral sclerosis	0.000691	0.00495	CbGeAlD
Regorafenib—PDGFRB—central nervous system—amyotrophic lateral sclerosis	0.000691	0.00494	CbGeAlD
Regorafenib—PDGFRB—cerebellum—amyotrophic lateral sclerosis	0.000675	0.00483	CbGeAlD
Regorafenib—ABL1—nervous system—amyotrophic lateral sclerosis	0.000639	0.00458	CbGeAlD
Regorafenib—KDR—brain—amyotrophic lateral sclerosis	0.000633	0.00453	CbGeAlD
Regorafenib—ABL1—central nervous system—amyotrophic lateral sclerosis	0.000616	0.00441	CbGeAlD
Regorafenib—ABL1—cerebellum—amyotrophic lateral sclerosis	0.000602	0.00431	CbGeAlD
Regorafenib—KIT—brain—amyotrophic lateral sclerosis	0.000561	0.00402	CbGeAlD
Regorafenib—PDGFRB—brain—amyotrophic lateral sclerosis	0.000548	0.00392	CbGeAlD
Regorafenib—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.000537	0.00384	CbGeAlD
Regorafenib—ABL1—brain—amyotrophic lateral sclerosis	0.000489	0.0035	CbGeAlD
Regorafenib—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.000478	0.00342	CbGeAlD
Regorafenib—ABCB1—embryo—amyotrophic lateral sclerosis	0.000414	0.00296	CbGeAlD
Regorafenib—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000379	0.00272	CbGeAlD
Regorafenib—CYP2B6—nervous system—amyotrophic lateral sclerosis	0.000372	0.00266	CbGeAlD
Regorafenib—CYP2B6—central nervous system—amyotrophic lateral sclerosis	0.000358	0.00256	CbGeAlD
Regorafenib—CYP2C8—brain—amyotrophic lateral sclerosis	0.000317	0.00227	CbGeAlD
Regorafenib—ABCG2—brain—amyotrophic lateral sclerosis	0.000308	0.00221	CbGeAlD
Regorafenib—CYP2B6—brain—amyotrophic lateral sclerosis	0.000284	0.00203	CbGeAlD
Regorafenib—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000281	0.00201	CbGeAlD
Regorafenib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.00027	0.00194	CbGeAlD
Regorafenib—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000265	0.00189	CbGeAlD
Regorafenib—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000236	0.00169	CbGeAlD
Regorafenib—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000199	0.00142	CbGeAlD
Regorafenib—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000191	0.00137	CbGeAlD
Regorafenib—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000187	0.00134	CbGeAlD
Regorafenib—ABCB1—brain—amyotrophic lateral sclerosis	0.000152	0.00109	CbGeAlD
Regorafenib—BRAF—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.76e-05	0.000111	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—IGF1—amyotrophic lateral sclerosis	2.75e-05	0.000111	CbGpPWpGaD
Regorafenib—KIT—Disease—ERBB4—amyotrophic lateral sclerosis	2.74e-05	0.00011	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—C3—amyotrophic lateral sclerosis	2.74e-05	0.00011	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CASP9—amyotrophic lateral sclerosis	2.73e-05	0.00011	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	2.73e-05	0.00011	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.67e-05	0.000108	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CD40LG—amyotrophic lateral sclerosis	2.65e-05	0.000107	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CD40LG—amyotrophic lateral sclerosis	2.64e-05	0.000106	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CASP9—amyotrophic lateral sclerosis	2.64e-05	0.000106	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.62e-05	0.000106	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.61e-05	0.000105	CbGpPWpGaD
Regorafenib—FGFR1—Disease—ERBB4—amyotrophic lateral sclerosis	2.6e-05	0.000105	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—ERBB4—amyotrophic lateral sclerosis	2.59e-05	0.000105	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.59e-05	0.000104	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—GSR—amyotrophic lateral sclerosis	2.59e-05	0.000104	CbGpPWpGaD
Regorafenib—RAF1—Axon guidance—VEGFA—amyotrophic lateral sclerosis	2.57e-05	0.000103	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.56e-05	0.000103	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	2.55e-05	0.000103	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.55e-05	0.000103	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—ERBB4—amyotrophic lateral sclerosis	2.53e-05	0.000102	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—C3—amyotrophic lateral sclerosis	2.51e-05	0.000101	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.51e-05	0.000101	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.49e-05	0.0001	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.48e-05	9.98e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—ERBB4—amyotrophic lateral sclerosis	2.47e-05	9.94e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—C3—amyotrophic lateral sclerosis	2.47e-05	9.94e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.46e-05	9.93e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.46e-05	9.93e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.45e-05	9.89e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—CASP9—amyotrophic lateral sclerosis	2.43e-05	9.81e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.4e-05	9.66e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.38e-05	9.6e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD40LG—amyotrophic lateral sclerosis	2.38e-05	9.59e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.38e-05	9.58e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.38e-05	9.58e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	2.37e-05	9.56e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.35e-05	9.49e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	2.35e-05	9.45e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—C3—amyotrophic lateral sclerosis	2.34e-05	9.44e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—ERBB4—amyotrophic lateral sclerosis	2.34e-05	9.42e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—C3—amyotrophic lateral sclerosis	2.34e-05	9.41e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—APOE—amyotrophic lateral sclerosis	2.33e-05	9.39e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.33e-05	9.38e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	2.32e-05	9.37e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	2.32e-05	9.37e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.32e-05	9.36e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD40LG—amyotrophic lateral sclerosis	2.32e-05	9.35e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.32e-05	9.34e-05	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.29e-05	9.22e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.28e-05	9.2e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—ERBB4—amyotrophic lateral sclerosis	2.26e-05	9.09e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.24e-05	9.04e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.23e-05	9.01e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.23e-05	8.99e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.23e-05	8.98e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	2.19e-05	8.82e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	2.18e-05	8.77e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.18e-05	8.77e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—APOE—amyotrophic lateral sclerosis	2.16e-05	8.7e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.14e-05	8.63e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.14e-05	8.6e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.13e-05	8.58e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.13e-05	8.58e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	2.13e-05	8.57e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CHAT—amyotrophic lateral sclerosis	2.12e-05	8.56e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.12e-05	8.56e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD40LG—amyotrophic lateral sclerosis	2.12e-05	8.55e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—APOE—amyotrophic lateral sclerosis	2.12e-05	8.55e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	2.12e-05	8.53e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.11e-05	8.5e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—C3—amyotrophic lateral sclerosis	2.1e-05	8.48e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—ERBB4—amyotrophic lateral sclerosis	2.08e-05	8.4e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.08e-05	8.39e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.07e-05	8.33e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.06e-05	8.29e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.05e-05	8.27e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—C3—amyotrophic lateral sclerosis	2.05e-05	8.26e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.04e-05	8.22e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.03e-05	8.17e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—APOE—amyotrophic lateral sclerosis	2.01e-05	8.11e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.01e-05	8.09e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—APOE—amyotrophic lateral sclerosis	2.01e-05	8.09e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2e-05	8.07e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2e-05	8.07e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.99e-05	8.04e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.98e-05	7.99e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.98e-05	7.96e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.96e-05	7.92e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.95e-05	7.88e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	1.95e-05	7.88e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	1.93e-05	7.78e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.92e-05	7.74e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.92e-05	7.72e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.91e-05	7.71e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.91e-05	7.69e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	1.91e-05	7.69e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—C3—amyotrophic lateral sclerosis	1.88e-05	7.56e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.86e-05	7.49e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.85e-05	7.44e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.84e-05	7.41e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.84e-05	7.4e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.84e-05	7.4e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.83e-05	7.38e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.83e-05	7.38e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.82e-05	7.34e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.82e-05	7.32e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—APOE—amyotrophic lateral sclerosis	1.81e-05	7.29e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.8e-05	7.27e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	1.8e-05	7.25e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.8e-05	7.24e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.79e-05	7.21e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	1.78e-05	7.18e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.78e-05	7.17e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.77e-05	7.13e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.75e-05	7.06e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.73e-05	6.97e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.71e-05	6.9e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.71e-05	6.88e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.7e-05	6.87e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.69e-05	6.8e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.69e-05	6.8e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.68e-05	6.77e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.67e-05	6.75e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.65e-05	6.64e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.64e-05	6.61e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.64e-05	6.6e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.63e-05	6.57e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.62e-05	6.54e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.62e-05	6.54e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—APOE—amyotrophic lateral sclerosis	1.61e-05	6.5e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	1.61e-05	6.47e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—PTGS2—amyotrophic lateral sclerosis	1.6e-05	6.43e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.6e-05	6.43e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.58e-05	6.38e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.57e-05	6.34e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.57e-05	6.31e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.56e-05	6.28e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.55e-05	6.26e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.54e-05	6.2e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.51e-05	6.1e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.51e-05	6.09e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.51e-05	6.08e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.49e-05	5.98e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—TP53—amyotrophic lateral sclerosis	1.48e-05	5.98e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—PTGS2—amyotrophic lateral sclerosis	1.48e-05	5.96e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.46e-05	5.9e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	1.46e-05	5.9e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.46e-05	5.88e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—PTGS2—amyotrophic lateral sclerosis	1.45e-05	5.86e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.43e-05	5.77e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.41e-05	5.68e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.41e-05	5.66e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.4e-05	5.63e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—APOE—amyotrophic lateral sclerosis	1.39e-05	5.59e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—APOE—amyotrophic lateral sclerosis	1.39e-05	5.59e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—PTGS2—amyotrophic lateral sclerosis	1.38e-05	5.56e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—PTGS2—amyotrophic lateral sclerosis	1.38e-05	5.54e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.37e-05	5.53e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.36e-05	5.48e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.36e-05	5.48e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—TP53—amyotrophic lateral sclerosis	1.36e-05	5.47e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.35e-05	5.43e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.34e-05	5.38e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.29e-05	5.19e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.27e-05	5.13e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.27e-05	5.1e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.25e-05	5.03e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PTGS2—amyotrophic lateral sclerosis	1.24e-05	4.99e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.23e-05	4.94e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.22e-05	4.91e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.22e-05	4.91e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.21e-05	4.89e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	1.18e-05	4.74e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.18e-05	4.74e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.17e-05	4.73e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.16e-05	4.69e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.16e-05	4.68e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.15e-05	4.64e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.14e-05	4.6e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.13e-05	4.55e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.12e-05	4.53e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—PTGS2—amyotrophic lateral sclerosis	1.1e-05	4.45e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.09e-05	4.41e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.05e-05	4.23e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.05e-05	4.22e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.05e-05	4.22e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.04e-05	4.18e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.03e-05	4.17e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1e-05	4.04e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.9e-06	3.99e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.81e-06	3.95e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.66e-06	3.89e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	9.65e-06	3.89e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.62e-06	3.88e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.51e-06	3.83e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.51e-06	3.83e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.45e-06	3.81e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.33e-06	3.76e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.15e-06	3.69e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	9.09e-06	3.66e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.96e-06	3.61e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.94e-06	3.6e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.93e-06	3.6e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.89e-06	3.58e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.88e-06	3.58e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.81e-06	3.55e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—APOE—amyotrophic lateral sclerosis	8.63e-06	3.48e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.63e-06	3.48e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.47e-06	3.41e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.45e-06	3.4e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.42e-06	3.39e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	8.27e-06	3.33e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.16e-06	3.29e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.07e-06	3.25e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.05e-06	3.25e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.02e-06	3.23e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.93e-06	3.19e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.87e-06	3.17e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.81e-06	3.15e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.74e-06	3.12e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.61e-06	3.07e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.61e-06	3.07e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.59e-06	3.06e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	7.31e-06	2.94e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.23e-06	2.91e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.18e-06	2.89e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.84e-06	2.75e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.78e-06	2.73e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.72e-06	2.71e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.65e-06	2.68e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	6.52e-06	2.63e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	6.37e-06	2.57e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.17e-06	2.48e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.09e-06	2.45e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.06e-06	2.44e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	5.95e-06	2.4e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.91e-06	2.38e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.75e-06	2.32e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.73e-06	2.31e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.19e-06	2.09e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.16e-06	2.08e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.01e-06	2.02e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.77e-06	1.92e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.6e-06	1.85e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.47e-06	1.8e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.36e-06	1.76e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.07e-06	1.64e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	3.92e-06	1.58e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.69e-06	1.08e-05	CbGpPWpGaD
